|
Emerging Markets Encouraged to Focus on Most Likely Counterfeits
Drugmakers breaking into emerging markets could see supply chain benefits and quicker product launches if these markets automatically registered U.S. Food and Drug Administration (FDA)-approved products before testing for quality issues, according to a new study.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives